Hypereosinophilic Syndrome, Workup & Variant-Directed Therapy

Diagnosis and variant-directed treatment of hypereosinophilic syndrome (HES), defined by persistent blood eosinophilia ≥1500/µL with eosinophil-mediated organ damage after excluding secondary causes. Routes by molecular/clinical variant: the myeloid variant (FIP1L1-PDGFRA and related fusions) responds to imatinib, while idiopathic/lymphoid HES is treated with corticosteroids and steroid-sparing mepolizumab. Emphasizes excluding Strongyloides (empiric ivermectin) before corticosteroids and testing for PDGFRA before assuming idiopathic disease.

Evidence tier: Expert consensus. Reflects expert-consensus criteria, not a prospectively validated instrument. Apply clinical judgment and local policy.

Decision points

  • Confirmed HES, or HE without organ damage?
  • Myeloid (clonal/PDGFRA) or lymphoid/idiopathic variant?

Do-not-miss pitfalls

  • Exclude and empirically treat Strongyloides (serology + ivermectin in at-risk/endemic-exposure patients) BEFORE starting corticosteroids, steroids can precipitate fatal disseminated strongyloidiasis (hyperinfection syndrome).
  • Test for FIP1L1-PDGFRA (and PDGFRB/FGFR1/PCM1-JAK2) BEFORE committing to corticosteroids, the myeloid variant responds to imatinib, not steroids, and missing it means months of ineffective steroid toxicity.
  • In PDGFRA-positive HES with cardiac involvement or elevated troponin, starting imatinib can trigger acute cardiac decompensation from rapid eosinophil lysis, co-administer corticosteroids for the first 1-2 weeks of imatinib.
  • HES is a diagnosis of exclusion, secondary (reactive) eosinophilia (parasites, drugs, atopy, malignancy, adrenal insufficiency) is far more common and must be ruled out before labeling primary HES.
  • Eosinophil-mediated cardiac damage (endomyocardial fibrosis, Löffler endocarditis) is the leading cause of HES morbidity and mortality, screen with troponin, ECG, echocardiography, and cardiac MRI regardless of symptom status.
  • Mepolizumab is FDA-approved for HES (2020) as a corticosteroid-sparing agent, escalate to it rather than chronically maintaining high-dose steroids in idiopathic/lymphoid disease.
  • The lymphoid variant (aberrant CD3−CD4+ T-cell clone) carries a risk of progression to peripheral T-cell lymphoma, these patients need ongoing hematologic surveillance, not just eosinophil control.
  • A markedly elevated serum tryptase or B12, splenomegaly, or marrow dysplasia points to a myeloid clone even when FIP1L1-PDGFRA is negative, pursue the other fusion genes and hematology referral.

Evidence & citations

  1. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(1):129-148. PMID 34533850
  2. Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397-1405. PMID 32956756
  3. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612. PMID 22460074
  4. Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103(8):2879-2891. PMID 15070659

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.